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Abstract: Tigecycline is a member of the glycylcycline class of antimicrobials, which is
structurally similar to the tetracycline class. It demonstrates potent in vitro activity against
causative pathogens that are most frequently isolated in patients with community-acquired
bacterial pneumonia (CABP), including (but not limited to) Streptococcus pneumoniae (both
penicillin-sensitive and -resistant strains), Haemophilus influenzae and Moraxella catarrhalis
(including β-lactamase-producing strains), Klebsiella pneumoniae, and ‘atypical organisms’
(namely Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila).
Comparative randomized clinical trials to date performed in hospitalized patients receiving tigecycline 100 mg intravenous (IV) × 1 and then 50 mg IV twice daily thereafter have
demonstrated efficacy and safety comparable to the comparator agent. Major adverse effects
were primarily gastrointestinal in nature. Tigecycline represents a parenteral monotherapy
option in hospitalized patients with CABP (especially in patients unable to receive respiratory fluoroquinolones). However, alternate and/or additional therapies should be considered
in patients with more severe forms of CABP in light of recent data of increased mortality in
patients receiving tigecycline for other types of severe infection.
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Community-acquired bacterial pneumonia (CABP) is a leading cause of morbidity
and mortality in the United States.1–3 An estimated 5–6 million cases per year result
in hospitalization rates of ∼20% and (among hospitalized patients) a mortality rate
of 12%.1–3 Organisms most commonly isolated in patients with CABP include
Streptococcus pneumoniae (S. pneumoniae) (the most common), Haemophilus
influenzae, Moraxella catarrhalis (M. catarrhalis), Klebsiella pneumoniae
(K. pneumoniae), and ‘atypical organisms’ (namely Chlamydophila pneumoniae
(C. pneumoniae), Mycoplasma pneumoniae (M. pneumoniae), and Legionella pneumophila (L. pneumophila)).4–6 Other Gram-negative bacilli and Staphylococcus aureus
infrequently cause CABP, except in patients with severe disease and/or select underlying comorbidities.4,6 Antimicrobial resistance among these organisms continues to be a
growing concern. For example, rates of multidrug-resistant S. pneumoniae have been
reported to be .30% worldwide, and the rates of β-lactamase-producing H. influenzae
ranges from 12% to 27%.7–9
Current published guidelines for the empiric treatment of CABP in hospitalized patients not admitted to the intensive care unit (ICU) generally include
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either monotherapy with a respiratory fluoroquinolone
(gemifloxacin, moxifloxacin, or levofloxacin) or a combination of a β-lactam (such as ceftriaxone or cefotaxime) in
combination with a macrolide.4–6 Alternative monotherapy
options in such patients unable to receive a respiratory
fluoroquinolone are lacking.
Tigecycline is a member of the glycylcycline class of
antimicrobials, which is structurally similar to the tetracycline
class.10 It possesses favorable activity in vitro against a broad
spectrum of aerobic Gram-positive, Gram-negative, anaerobic, and ‘atypical’ microorganisms, including those most
frequently associated with CABP.10 Previously published
controlled clinical trials have established its effectiveness
in the treatment of both complicated skin and skin structure
infections (cSSSIs) and complicated intra-abdominal infections (cIAIs).11–14 More recently, tigecycline has been studied
for the treatment of CABP.15–17 Our objective is to provide an
overview of tigecycline’s activity, clinical efficacy, safety,
and potential role in the treatment of CABP.

Overview of tigecycline
Pharmacology
Tigecycline acts by binding to the bacterial ribosomal subunit
30 S, resulting in inhibition of protein synthesis.11 The resulting
activity is time-dependent bacteriostatic against most organisms, although bactericidal activity has been observed with
S. pneumoniae and L. pneumophilia isolates.11 The in vitro
post-antibiotic effect of tigecycline against Staphylococcus
aureus, S. pneumoniae, and Gram-negative organisms has
ranged from .3 to 4.1, 8.9, and 2 to 5 h, respectively.11
Tigecycline’s in vitro activity appears unaffected by
β-lactamase production, alterations in the target site, or
target enzymes.11 It also appears to be unaffected by most
resistance mechanisms affecting the tetracyclines (such as
ribosomal protection and select efflux pumps).18–25 However,
the most common mechanisms of resistance to tigecycline
does appear to involve efflux pumps. 11 One particular
type of efflux pump (known as the ‘resistance nodulation
d ivision’) has been noted in isolates of Pseudomonas
aeruginosa, Acinetobacter baumannii (A. baumannii),
Serratia marcescens, and Enterobacter cloacae.26–29 Such
efflux pumps, especially those found with A. baumannii,
are associated with multidrug resistance.29 Efflux pumps to
tigecycline have also been observed in Burkholderia spp.30
In K. pneumoniae, resistance to tigecycline expression of
the mutant ramR gene resulted in alterations of the bacterial
genome such as deletions, insertions, and point mutations
that led to reduced susceptibility to tigecycline.31
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Microbiology
Tigecycline is a broad-spectrum antimicrobial agent that
has in vitro activity against a variety of facultative aerobic
Gram-positive, Gram-negative, and anaerobic bacteria
(Table 1). According to the Clinical Laboratory Standards
Institute, the minimum inhibitory concentration (MIC)
considered susceptible to tigecycline is #0.5 mg/L for

Staphylococcus aureus (including methicillin-resistant
organisms), #0.25 mg/L for non–Streptotoccus pneumoniae,
Streptococcus spp, and Enterococcus faecalis isolates.32,33
For S. pneumoniae, the susceptibility MIC breakpoint
is #0.06 mg/L.32,33 The MIC considered susceptible for
Enterobacteraceae and H. influenzae is #2 and #0.25 mg/L,
respectively. 32,33 Anaerobes are deemed susceptible to
tigecycline if the MIC is #4 mg/L.33,34
Tigecycline demonstrates potent activity in vitro data
against most relevant Gram-positive organisms. Isolates of
Staphylococcus aureus (n = 8765) displayed 99.4% susceptibility, with MIC90 and ranges of 0.5 and #0.016–1 mg/L,
respectively.35 In vitro susceptibilities of coagulase-negative
Staphylococcus (n = 3570), Enterococcus spp (n = 3258),
β-hemolytic Streptotocci (n = 769), and viridans group
Streptococci (n = 378) were 97.5%, 92.7%, 99.7%, and
98.1%, respectively.35 Of particular relevance to CABP, tigecycline displays potent in vitro activity against S. pneumoniae.
A total of 92.7% of 605 isolates were susceptibile to tigecycline, with MIC90 and ranges of #0.12 and #0.12–1 mg/L,
respectively.35 Tigecycline’s activity also includes penicillinintermediate and penicillin-resistant S. pneumoniae
organisms, with 90.2% (n = 1077) and 91.2% (n = 555)
susceptibility, respectively, for North American isolates.36
In addition, a tigecycline MIC of 0.12 mg/L was reported
against a fluoroquinolone-resistant S. pneumoniae.37 Although
not common, community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA) may cause CABP
(most notably in patients with post-influenza bacterial
pneumonia).38–40 In such cases, mortality rates approach 30%.39
CA-MRSA is often characterized by the presence of
Panton–Valentine leukocidin (PVL) cytotoxin, although
its contribution to organism virulence is controversial.38
Tigecycline exhibits favorable in vitro activity against
CA-MRSA isolates (98.2% susceptibility rate) (n = 1989).41
Tigecycline has also been reported to reduce the expression
of the PVL gene, resulting in a 10-fold reduction in toxin
production.41,42
Tigecycline also exhibits potent in vitro activity against
many Gram-negative organisms, with notable exceptions including Proteus and Pseudomonas spp.35 In one
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Table 1 In vitro activity of tigecycline against common CABP respiratory pathogensa
Bacteria
Typical pathogens
S. pneumoniae
S. pneumoniae, penicillin-intermediate susceptible
S. pneumoniae, penicillin resistant
H. influenzae
H. influenzae, β-lactamase positive
Klebsiella pneumoniae
Moraxella catarrhalis
Atypical pathogens
Chlamydia pneumoniae
Legionella sppc
Mycoplasma pneumoniae

No. of isolates

MIC90

MIC range (in mg/L)

References

6456
1077b
891
6070
1346
10,644
2314

0.06
0.06
0.06
0.5
0.5
2
0.5

#0.008–1
NR
#0.008–0.25
#0.008–2
#0.008–2
#0.008–16
#0.06–4

95
36
95
95
95
95
43

10
100
30

0.125
8
0.25

0.125–0.25
0.5–8
0.06–0.25

51
52,53
50

Notes: aAccording to the Clinical Laboratory Standards Institute (CLSI), the MICs considered susceptible are as follows: S. pneumoniae # 0.06 mg/L, H. influenzae #0.25 mg/L,
and Enterobacteraciae # 2 mg/L; bData from North American isolates; cIsolates (n = 50) of Legionella pneumophilia are represented.
Abbreviations: CABP, community-acquired bacterial pneumonia; MIC, minimum inhibitory concentration; NR, not reported; S. pneumoniae, Streptococcus pneumoniae;
H. influenzae, Haemophilus influenzae.

i ntercontinental study involving over 26,000 isolates,
many Gram-negative organisms displayed over 95% susceptibility to tigecycline.35 This included Escherichia coli
(E. coli) (n = 3217; 0.25 and 0.03–4 mg/L), Enterobacter
spp (n = 801; 2 and 0.06–8 mg/L), and Klebsiella spp
(n = 1503; 1 and 0.06–8 mg/L) for isolate numbers, MIC90,
and range, respectively.35 Other Gram-negative organisms
that are often susceptible to tigecycline include Serratia
spp (n = 294, 94.6% susceptible), Stenotrophomonas
maltophilia (n = 203, 93.1% susceptible), and Acinetobacter spp (n = 326, 94.5% susceptible).35 Of relevance to
Gram-negative pathogens causing CABP, tigecycline displays potent in vitro activity against H. influenzae (including resistant isolates such as β-lactamase producers) and
M. catarrhalis.36,43 In one study of respiratory tract organisms, M. catarrhalis isolates (n = 2314) demonstrated
tigecycline MIC90 and ranges of 0.5 and #0.06–4 mg/L.43
In another study, North American H. influenzae isolates
had MIC90 and ranges of 0.5 and #0.008–2 mg/L for
β-lactamase-producing H. influenzae (n = 904) and 0.5
and 0.015–2 mg/L for β-lactamase negative, ampicillinresistant H. influenzae isolates (n = 34), respectively.36
While generally not of concern as etiologic agents in
CABP, tigecycline displays favorable in vitro activity
against extended-spectrum β-lactamase (ESBL)-producing E. coli and K. pneumoniae.44,45 For example, 90.7%
of 150 isolates of ESBL-producing K. pneumoniae were
considered susceptible to tigecycline.46 A regional study
examined ESBL-producing E. coli isolates and reported
susceptibilities of 94.7% (n = 19), 89.2% (n = 65), and
95.5% (n = 22) in the East North Central, Middle Atlantic,
and South Atlantic regions of the USA, respectively.47
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The in vitro activity of tigecycline against anaerobes has
been studied, and tigecycline displayed excellent potency
against Clostridium perfringens, Peptostreptococcus micros,
Bacteroides fragilis, Bacteroides thetaiotaomicron, and Bacteroides uniformis.48 While not frequent causes of CABP, anaerobic pathogens may be of concern in cases of aspiration.49
Organisms such as C. pneumoniae, M. pneumoniae,
and L. pneumophilia have also been reported as etiologies
to CABP.50–53 The MIC90 and ranges for tigecycline were
0.125 and 0.125–0.25 mg/L for C. pneumoniae (n = 10), 8
and 0.5–8 mg/L for Legionella spp (n = 100), and 0.25 and
0.06–0.25 mg/L for M. pneumoniae.50–53

Pharmacokinetics/pharmacodynamics
Tigecycline exhibits linear kinetics, with a two-compartment
model following intravenous (IV) administration.54,55 Data
from healthy volunteers (n = 103) receiving tigecycline 100 mg
as a loading dose followed by 50 mg every 12 h demonstrated
a maximum plasma concentration (Cmax) of 0.63 µg/mL after a
60-min infusion and a minimum plasma concentration (Cmin) of
0.13 µg/mL.11,54 The area under the plasma concentration–time
curve from 0 to 24 h (AUC0–24) was 4.7 µg ⋅ h/mL.54 Similar
pharmacokinetic parameters have been noted in phase III clinical studies of patients with cSSSIs and cIAIs. 56,57
Tigecycline is highly protein bound (71%–89%) at plasma
drug concentrations of 0.1–1.0 µg/mL and exhibits a large
volume of distribution (Vd) at steady state of 7–9 L/kg in
healthy volunteers.11,54 Animal and human studies have demonstrated that tigecycline can distribute into various tissues
and body fluids (such as the lungs, skin, peritoneal fluid,
gallbladder, colon, heart, liver, meninges, and bone).11,58–64
In a study of adult patients (n = 104) undergoing medical
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or surgical procedures, tigecycline concentrations were
evaluated 4 h after the administration of 100 mg over
30 min.63 The highest concentration of tigecycline was found
in the bile. The mean ratio of tigecycline in the tissue to
serum (expressed as AUC0–24) was 537 in the bile, 23 in the
gallbladder, 2.6 in the colon, 2.0 in the lung, 0.41 in bone,
0.31 in synovial fluid, and 0.11 in cerebrospinal fluid.
Lung penetration of tigecycline has been evaluated
in healthy adults (n = 30) after receiving a loading dose
of 100 mg of tigecycline followed by six doses of 50 mg
every 12 h.60 The AUC0–12 was 1.73 µg ⋅ h/mL in the serum,
134 µg ⋅ h/mL in the alveolar cells (ACs), and 2.28 µg ⋅ h/mL
in the epithelial lining fluid (ELF). The corresponding Cmax
was 0.72, 15.2, and 0.37 µg/mL, respectively. In adult
critically ill mechanically ventilated patients (n = 3), mean
tigecycline concentrations 4 h following the infusion were
0.36 ± 0.20, 0.02 ± 0.01, and 8.96 ± 0.15 mg/L in the plasma,
ELF, and ACs, respectively, after receipt of 100 mg followed
by 50 mg every 12 h.65 The ratios of ELF and AC concentrations relative to plasma concentrations were 0.06 ± 0.02
and 34.3 ± 7.8, respectively. Although plasma, ELF, and
AC concentrations are comparable to healthy volunteers,
the penetration of tigecycline into the extracellular lung
compartment of these critically ill patients with underlying
pulmonary pathology (as noted by the ELF to plasma ratio)
was low.60,66 Although ELF is an intrapulmonary site, concentrations within this fluid are believed to be important in
reflecting potency against extracellular organisms (such as
S. pneumoniae and K. pneumonia).65,66
Tigecycline is minimally metabolized to nonactive
metabolites of glucuronide, its epimer M1 and M2, and
N-acetyl-9-aminominocycline (M6). 11,67,68 The primary
route of elimination of tigecycline is as unchanged drug and
metabolites through the feces (59%) and biliary tract.67 Renal
excretion (33%) and glucuronidation are secondary routes of
elimination. Tigecycline has a terminal half-life of 37–67 h
and a total systemic clearance of 0.2–0.3 L/h/kg.54
The pharmacokinetic profile of tigecycline has been
evaluated in several different special patient populations.
No differences have been noted based on age (18 to .75),
gender, or race. 69,70 Patients with renal insuff iciency
(creatinine clearance # 30 mL/min) and dependent on
hemodialysis also did not demonstrate alterations in their
pharmacokinetic profiles.71 Tigecycline is not significantly
removed with hemodialysis.71 Patients with severe hepatic
impairment (Child–Pugh class C) demonstrated a 43%
increase in half-life and a 55% decrease in
t igecycline clearance. 72 It is r ecommended that the
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maintenance dose of tigecycline should be reduced to 25 mg
every 12 h in these individuals.11,72,73 In contrast, no adjustment in doses are necessary for patients with mild to moderate (Child–Pugh class A or Child–Pugh class B) hepatic
impairment.11,72
Based on animal and the clinical data, the AUC to MIC
ratio (AUC/MIC) is most likely to be the best predictor of
efficacy with tigecycline.37,69,74 Studies in cSSSIs and cIAIs
have suggested that the AUC0–24/MIC of $17.9 and $6.96,
respectively, were predictive of favorable clinical response
and microbiological eradication.74,75 In two phase III CABP
studies (n = 68), patients receiving a loading dose of 100 mg
followed by 50 mg every 12 h had a median AUC0–24/MIC
of 55.5 (5.2–179.5) with the MICs ranging from 0.03 to
1.0 mg/L for mono- and poly-microbial S. pneumoniae
infections. 76 Due to the low incidence of clinical and
microbiological failures, the authors felt that a clear pharmacokinetics/pharmacodynamics relationship could not
be established. However, a Classification and Regression
Tree (CART)-derived AUC/MIC breakpoint of 64 was predictive of time to fever resolution, since the median time
to fever resolution for AUC/MIC of $64 and ,64 were
12 and 24 h, respectively (P = 0.05). In contrast, evaluation of a phase III hospital-acquired pneumonia (HAP)
study (n = 61) in which patients received standard doses
of tigecycline, a CART-derived AUC/MIC breakpoint of
5.75 was significantly associated with clinical success in
patients (P # 0.02).76 Only 43.2% (7/16) patients with an
AUC/MIC of ,5.75 achieved clinical success, while 80%
(36/45) of patients with an AUC/MIC of $5.75 achieved
clinical success (P = 0.011).
In regards to the treatment of bacteremia, low Cmax concentrations obtained after standard dosing of tigecycline are
concerning, since it approaches the MICs of organisms most
commonly encountered.77 Furthermore, tigecycline concentrations rapidly decline once the Cmax is reached. Animal
models in neutropenic mice have demonstrated that unbound
serum concentrations of tigecycline need to be above the
MIC of the organism for at least 50% of the dosing interval
in order to achieve maximum effectiveness.63,69,78,79 Therefore,
organisms would need to have a relatively low MIC to tigecycline in order to achieve this pharmacodynamic target in
bacteremia.60,80 To address this issue, case reports with higher
dosing schemes of tigecycline (200–400 mg as the loading
dose followed by 100–200 mg every 24 h) have reported success in the treatment of multidrug-resistant K. pneumoniae
and A. baumannii with higher dosing schemes in order to
maximize the AUC/MIC.80–82
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Effectiveness of tigecycline
in the treatment of CABP
Results of two noninferiority, randomized, double-blind,
multinational, phase III studies have been published, which
compared the safety and efficacy of tigecycline in comparison with levofloxacin.15–17 Febrile, hospitalized adults with
CABP (confirmed by chest radiograph and at least two of
the following: symptoms consistent with a bacterial respiratory infection, leukocytosis, or hypoxemia) who required
IV antibiotics were included. Those who failed outpatient
fluoroquinolones previously, were recently hospitalized,
resided in a long-term care facility (within 14 days), required
ICU admission, or had known or suspected infections
(P. aeruginosa, Legionella pneumonia, or active tuberculosis)
were excluded. Patients were randomized to receive either tigecycline (100 mg IV × 1, then 50 mg IV twice daily thereafter)
or levofloxacin (500 mg IV daily (one of the trials also had
the option for 500 mg IV twice daily at the discretion of the
investigator)). In one of the two trials, patients in either group
could be switched to oral levofloxacin at the discretion of the
investigator after 3 days of IV antibiotics. The total duration of
antimicrobial treatment was 7–14 days in both of these studies.
The primary end points were clinical response at the test of cure
(TOC) in both the clinical modified intent-to-treat (c-mITT) and
the clinically evaluable (CE) populations. In these studies, ‘cure’
required the improvement or resolution of clinical signs and
symptoms attributable to CABP, improvement or no change on
chest radiograph, and no additional antimicrobials.15–17
Of the 859 patients included in the intent-to-treat (ITT)
population, 797 and 574 were included in the c-mITT and
CE populations, respectively. For the tigecycline group, the
mean age was 52.6 years (±18) with 57.3% male patients;
the levofloxacin group’s mean age was 51.9 years (±18.7)
with 62.8% male patients. Fine pneumonia severity index
scores and confusion, urea nitrogen, respiratory rate, blood
pressure (CURB-65) criteria were similar among the groups,
with 80% of the population having scores of I–III for Fine
and 92% having scores of 0–2 for CURB-65. Concomitant
diseases (including chronic obstructive pulmonary disease,
diabetes, liver and renal disease, heart failure and cerebrovascular diseases, as well as cancer) were also comparable
among the two treatment groups. In one of the studies,
90% and 88% of the tigecycline and levofloxacin groups
were switched to oral antibiotics after a median of 3.9 and
3.3 days, respectively.15–17 In the first of the trials, a clinical
cure rate for the CE and c-mITT populations were 90.6%
versus 87.2% (absolute difference 3.4% (95% confidence
interval (95% CI): −4.4% to 11.2%)) and 78.0% versus
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77.8% (absolute difference 0.2% (95% CI: 8.5%–8.9%))
for tigecycline and levofloxacin treatments, respectively.
Similar observations were made in the second trial. Success rates in the CE and c-mITT populations were 88.9%
versus 85.3% (absolute difference 3.6% (95% CI: −4.5% to
11.8%)) and 83.7% versus 81.5% (absolute difference 2.0%
(95% CI: −5.5% to 9.6%)) in tigecycline and levofloxacin
groups, respectively. No differences were noted in clinical
cure rates among respiratory pathogens, including both typical and atypical organisms. To be considered noninferior,
the lower limit of the 95% CI could not exceed −15% for
the absolute difference. Thus, tigecycline was considered
noninferior to levofloxacin in both studies.15,16
The safety and efficacy of tigecycline has also been compared to other therapies (such as imipenem–cilastatin) in other
patient populations with pneumonia, most notably HAP (including ventilator-associated pneumonia (VAP) patients).83 In this
phase III, multicenter, multinational, double-blind randomized
trial, tigecycline failed to meet the prespecified noninferiority
criteria (the lower limit of the 95% CI could not exceed −15%
for the absolute difference) for the coprimary endpoints of
clinical response rates at the TOC in the CE (67.9% vs 78.2%,
absolute difference −10.4% (95% CI: −17.8% to −3%))
and c-mITT (62.7% vs 67.6%, absolute difference −4.8%
(95% CI: −11.0% to 1.3%)) in the tigecycline and imipenem
groups, respectively. In the VAP subgroup, there were lower
cure rates (47.9% vs 70.1%), and higher rates of mortality
(19.1% vs 12.3%) were seen in tigecycline patients relative to
those receiving imipenem–cilastatin. (See further discussion
of mortality in the safety and tolerability section.) Patients
with VAP and bacteremia at baseline had significantly greater
mortality with 50% (9/18) in the tigecycline population versus
7.7% (1/13) in the comparator group.83 Until further studies are
performed, tigecycline should not be recommended for these
types of patients. As of May 2010, this was an added component of the ‘Warnings and Precaution’ section of the Tygacil®
package insert.11
Case reports of tigecyclines effectiveness in the treatment of pneumonia by various organisms including
Mycobacterium chelonae,84 multidrug-resistant Stenotrophomonas maltophilia,85 and carbapenemase-producing
K. pneumoniae86 have been documented. However, until
further data are available, tigecyclines routine use against
these organisms cannot be recommended.

Safety and tolerability of tigecycline
Overall, tigecycline was well tolerated in phase III clinical
studies for the treatment of CABP and was comparable to
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those studies performed with tigecycline in the treatment of
cSSSIs and cIAIs. The most common adverse effect reported
was nausea (20.8% in community-acquired pneumonia
(CABP) studies; 34.5% in cSSSIs studies; 24.4% in cIAIs
studies) and vomiting (13.2% in CABP studies; 19.6% in
cSSSIs studies; 19.2% in cIAIs studies).12–17,87 Using the
National Cancer Institute Common Toxicity Criteria, the
nausea and vomiting was characterized as mild to moderate in severity in most patients in the CABP studies, and
only led to discontinue therapy in 14 patients.17 Factors that
have been shown to be associated with a higher incidence
of nausea and vomiting secondary to tigecycline therapy
include female gender, ,65 years of age, and non-European
descent.11 Furthermore, altering the infusion rate and the
use of antiemetics have not been beneficial in prevention of
such reactions.11,54 Administration with food may improve
tolerability.11
Pooled data from the CABP studies utilizing the mITT
population (n = 846) reported more drug-related adverse
events with tigecycline compared to the levofloxacin
(47.9% vs 37.4%, respectively (P , 0.01)).15–17 The most
common adverse effects noted in the studies were nausea (20.8% vs 6.6%) and vomiting (13.2% vs 3.3%) in
tigecycline- and levofloxacin-treated patients, respectively
(P , 0.001).17 Levofloxacin had a higher incidence of alanine
aminotransferase (6.4% versus 2.6%) and aspartate amino
transferase (5.9% vs 2.1%) elevations relative to tigecycline,
respectively (P , 0.01).17 Other adverse events such as
diarrhea, phlebitis, and headache were statistically similar
among treatment groups.17 Serious adverse events resulting
in extended hospitalizations, readmission to the hospital or
life-threatening effects (9.9% vs 10.9%), drug discontinuation secondary to adverse effects (6.1% vs 8.1%), and the
incidence of death not related to study drug (2.8% vs 2.6%)
were comparable between tigecycline and levofloxacin
groups, respectively.17 Only one case of Clostridium difficile
infection was reported in the tigecycline arm.17 Other more
commonly reported adverse effects with tigecycline include
diarrhea (7.5%), phlebitis (4%), and headache (3.5%).17
Other additional adverse effects reported with tigecycline
from postmarketing surveillance since its food and drug
administration (FDA) approval include anaphylaxis and
anaphylactoid reactions, acute pancreatitis, elevated liver
function tests, hyperbilirubinemia, jaundice, and hepatic
cholestasis.11,88–90
Recent, pooled analysis from 13 phase III and IV clinical
studies evaluating the use of tigecycline (n = 3788) versus
other antibiotics (n = 3646) in the treatment of various serious
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infections have demonstrated an increased risk with the use
of tigecycline for all-cause mortality (4% vs 3%, (adjusted
risk difference based on a random effects model stratified by
trial weight 0.6; 95% CI: 0.1, 1.2)).11,91 The increase in mortality was particularly noted for cSSSIs, cIAIs, diabetic foot
infections, and in HAP patients with VAP. Although mortality
rates in these infections individually did not reach statistical
significance, the incidence was higher for each infection in
the tigecycline group and when pooled, there was a statistically significant difference. In patients with CABP, all-cause
mortality rates of 2.8% in the tigecycline arm (12/424) compared to 2.6% in the alternate treatment arm (11/422) (risk
difference 0.3 (95% CI: −2.0, 2.4)). In patients with HAP,
the incidence of all-cause death was 14.1% (66/467) in the
tigecycline arm versus 12.2% (57/467) in the comparator
arm (risk difference 0.60.2 (95% CI: −2.4, 6.3)). Mortality rates in patients with VAP were 19.1% (25/131) versus
12.3% (15/122) for tigecycline and the comparator arm,
respectively (risk difference: 6.8; 95% CI: −2.1, 15.7). It has
been speculated that this increased incidence of mortality in
the tigecycline arms may have been due to progression of
infection while on therapy, possibly secondary to the static
nature of the drug; however, there is limited data currently
to support that bactericidal drugs are more efficacious than
bacteriostatic drugs.92
Tigecycline should be avoided in pregnant women
(pregnancy category D) and in growing children due to an
accumulation of the drug in bones; thus resulting a delay
in ossification.11,58,63 Additionally, similar to tetracyclines,
teeth discoloration during tooth development may occur from
the use of tigecycline and should, therefore, be avoided in
children below the age of eight.11

Drug interactions
Tigecycline is neither metabolized nor does it cause alterations to the cytochrome P450 system; thus, drug interactions mediated through this system have not been identified
and significant drug interactions have not been reported.11
Although studies in healthy volunteers administered tigecycline concomitantly with digoxin failed to detect any
significant drug interactions, the clearance of the R and
S enantiomers of warfarin were decreased.11,93,94 Therefore,
the international normalized ratio and signs and symptoms
of bleeding should be monitored if patients are receiving
tigecycline concurrently with warfarin.11,94 Additionally,
similar to other antibiotics, concurrent administration of
tigecycline with oral contraceptives may reduce the efficacy
of these agents.11
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Health care resource utilization
perspective

Society of Critical Care Medicine (speaker), American Society
of Microbiology (speaker).

In an analysis of health care resource utilization data from
CABP patients receiving either tigecycline (n = 393) or levofloxacin (n = 403), no difference was reported between the
groups in terms of mean length of hospital stay (9.8 days for
each group; P = 0.883) or mean duration of study antibiotic
(9.8 days tigecycline vs 10 days levofloxacin group; P = 0.511).
Additionally, there was no difference between groups in the
rate of rehospitalization, admission to the ICU or emergency
room, use of home health, or admission to the nursing home.
The need for concurrent antibiotics during or after discharge
was lower in the tigecycline group compared to the levofloxacin
group (5.6% vs 11.7% (P = 0.002), respectively).17
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related to data obtained in patients with other forms of severe
infection, including HAP.
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